CA2627351C - Lipophilic vehicle-based dual controlled release matrix system - Google Patents

Lipophilic vehicle-based dual controlled release matrix system Download PDF

Info

Publication number
CA2627351C
CA2627351C CA2627351A CA2627351A CA2627351C CA 2627351 C CA2627351 C CA 2627351C CA 2627351 A CA2627351 A CA 2627351A CA 2627351 A CA2627351 A CA 2627351A CA 2627351 C CA2627351 C CA 2627351C
Authority
CA
Canada
Prior art keywords
agents
rate controlling
soft capsule
matrix
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2627351A
Other languages
English (en)
French (fr)
Other versions
CA2627351A1 (en
Inventor
Karunakar Sukuru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Patheon Softgels Inc
Original Assignee
Banner Pharmacaps Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banner Pharmacaps Inc filed Critical Banner Pharmacaps Inc
Publication of CA2627351A1 publication Critical patent/CA2627351A1/en
Application granted granted Critical
Publication of CA2627351C publication Critical patent/CA2627351C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2627351A 2005-10-26 2006-10-26 Lipophilic vehicle-based dual controlled release matrix system Expired - Fee Related CA2627351C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73051405P 2005-10-26 2005-10-26
US60/730,514 2005-10-26
PCT/US2006/041722 WO2007050724A2 (en) 2005-10-26 2006-10-26 Lipophilic vehicle-based dual controlled release matrix system as capsule fill

Publications (2)

Publication Number Publication Date
CA2627351A1 CA2627351A1 (en) 2007-05-03
CA2627351C true CA2627351C (en) 2012-05-01

Family

ID=37968540

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2627351A Expired - Fee Related CA2627351C (en) 2005-10-26 2006-10-26 Lipophilic vehicle-based dual controlled release matrix system

Country Status (6)

Country Link
US (1) US8293270B2 (enExample)
EP (1) EP1951208A2 (enExample)
JP (2) JP5406529B2 (enExample)
CN (1) CN101351196B (enExample)
CA (1) CA2627351C (enExample)
WO (1) WO2007050724A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2904546T3 (es) 2006-02-03 2022-04-05 Opko Renal Llc Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
SI2037936T1 (sl) 2006-06-21 2014-11-28 Opko Renal, Llc Postopek zdravljenja in prepreäśevanja sekundarnega hiperparatiroidizma
CA2683628C (en) 2007-04-25 2018-03-06 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
FI3225243T3 (fi) 2007-04-25 2025-10-13 Opko Renal Llc Menetelmä sekundaarisen hyperparatyreoosin turvalliseen ja tehokkaaseen hoitoon ja ehkäisyyn kroonisen munuaistaudin yhteydessä
PT2148661E (pt) 2007-04-25 2013-03-06 Proventiv Therapeutics Llc Composições orais de libertação controlada compreendendo um composto de vitamina d e veículo ceroso
CA2689434C (en) * 2007-06-04 2017-09-26 Shear/Kershman Laboratories, Inc. Tamper resistant lipid-based oral dosage form for opioid agonists
US8177950B2 (en) * 2007-11-21 2012-05-15 Tennessee Technological University Thermoresponsive microparticle composite hydrogels for electrophoresis
US8962239B2 (en) 2008-04-02 2015-02-24 Opko Renal, Llc Methods useful for vitamin D deficiency and related disorders
JP5613396B2 (ja) * 2008-10-22 2014-10-22 参天製薬株式会社 腸管吸収性を改善する医薬組成物
CN105796530A (zh) 2010-03-29 2016-07-27 赛特克罗公司 用于降低甲状旁腺水平的方法和组合物
WO2013076305A1 (en) 2011-11-25 2013-05-30 Danmarks Tekniske Universitet Formulation of solid nano-sized particles in a gel-forming system
WO2014060856A1 (en) * 2012-10-16 2014-04-24 Wockhardt Limited Pharmaceutical compositions of diclofenac or salts thereof
WO2014060857A1 (en) * 2012-10-19 2014-04-24 Wockhardt Limited Pharmaceutical compositions of diclofenac or salts thereof
US10420729B2 (en) * 2013-03-15 2019-09-24 R.P. Scherer Technologies, Llc Abuse resistant capsule
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
EP3501510B1 (en) 2014-02-28 2020-07-01 Banner Life Sciences LLC Controlled release enteric soft capsules of fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US10772842B2 (en) 2015-01-09 2020-09-15 Patheon Softgels Inc. Abuse-deterrent opioids
US10772841B2 (en) 2014-04-07 2020-09-15 Patheon Softgels Inc. Opioid abuse-deterrent controlled release formulations
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
UA129792C2 (uk) 2016-03-28 2025-08-06 Ейрджен Фарма Лтд. Способи лікування вітаміном d
WO2017189621A1 (en) * 2016-04-26 2017-11-02 Symbiotic Health Inc. Stable macroemulsion for oral delivery of solubilized peptides, protein, and cellular therapeutics
EP3765002B1 (en) * 2018-03-15 2025-03-05 Cerecin Inc. Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
CN113301884A (zh) * 2018-09-13 2021-08-24 夫特弗制药私人有限公司 非水性化疗口服悬浮液
EP3863603A1 (en) * 2018-10-08 2021-08-18 Chanelle Pharmaceuticals Manufacturing Ltd. A soft-gel capsule formulation, method of manufacture and use thereof
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2016A (en) * 1841-03-26 Mode of constructing fireplaces and chimney-staoks ii
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
CA2017916C (en) * 1989-06-07 1999-02-02 Minoru Aoki Etoposide preparations
DE69226950T2 (de) * 1991-04-08 1999-05-12 Nippon Shinyaku Co., Ltd., Kyoto Kapsel mit Langzeitwirkung fuer die Adhäsion im Gastrointestinaltrakt
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
CN1133558A (zh) * 1993-10-29 1996-10-16 雷克特和科尔曼产品有限公司 可发泡的明胶胶囊填充药物
GB9322314D0 (en) 1993-10-29 1993-12-15 Scherer Ltd R P Foam generating capsules
US5447729A (en) * 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
FR2739558B1 (fr) * 1995-10-05 1997-11-28 Innothera Lab Sa Forme galenique unitaire pour hormonotherapie locale de la secheresse vaginale
FR2748209B1 (fr) * 1996-05-06 1998-06-05 Adir Composition pharmaceutique a base de matrices lipophiles stabilisees pour la liberation controlee de principes actifs
US6027746A (en) * 1997-04-23 2000-02-22 Warner-Lambert Company Chewable soft gelatin-encapsulated pharmaceutical adsorbates
IT1291362B1 (it) * 1997-05-13 1999-01-07 Vectorpharma Int Composizioni farmaceutiche multicomponente bifasiche contenenti sostanze atte a modificare la partizione dei principi attivi
JP4139909B2 (ja) * 1997-06-12 2008-08-27 キャタレント・ジャパン株式会社 ソフトカプセル用基剤
GB2328443B (en) * 1997-08-21 2001-09-05 Reckitt & Colmann Prod Ltd In situ formation of pharmaceutically acceptable polymeric material
BE1011363A3 (fr) * 1997-09-11 1999-08-03 Smb Technology Capsules semi-solides autoemulsionnables matricielles a action prolongee.
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
GB2331458B (en) 1997-11-21 2002-07-31 Gursharan Singh Moonga Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine
JP2002509103A (ja) 1998-01-20 2002-03-26 アプライド・アナリティカル・インダストリーズ，インコーポレイテッド 経口液体組成物
FR2782006B1 (fr) * 1998-08-07 2002-04-19 Gattefosse Ets Sa Composition a liberation prolongee apte a former une micro-emulsion
US6251426B1 (en) * 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
AU7716100A (en) 1999-09-27 2001-04-30 American Cyanamid Company Pharmaceutical carrier formulation
WO2001034119A2 (en) 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
DE60040729D1 (de) * 1999-12-20 2008-12-18 Shiseido Co Ltd Zubereitungen zur äusseren anwendung auf der haut enthaltend diethoxyethylsuccinat
US6491950B1 (en) * 2000-08-07 2002-12-10 Kos Pharmaceuticals, Inc. Controlled release pharmaceutical composition
US6524615B2 (en) * 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
US20030105141A1 (en) 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
US20030203030A1 (en) * 2002-01-18 2003-10-30 Control Delivery Systems, Inc. Polymeric gel delivery system for pharmaceuticals
IL164163A0 (en) 2002-04-09 2005-12-18 Pharmacia Corp Process for preparing a finely self-emulsifiable pharmaceutical composition
FR2838349B1 (fr) * 2002-04-15 2004-06-25 Laurence Paris Compositions liquides pour capsules molle a liberation prolongee et leur procede de fabrication
WO2003088950A1 (en) * 2002-04-18 2003-10-30 President And Fellows Of Harvard College System for enhanced targeted delivery
US20040033257A1 (en) * 2002-05-30 2004-02-19 Strides Inc. Pharmaceutical formulation in a drug delivery system and process for preparing the same
AU2003247876B2 (en) * 2002-07-05 2006-10-05 Collegium Pharmaceutical, Inc Abuse-deterrent pharmaceutical compositions of opiods and other drugs
CN1688294A (zh) 2002-10-01 2005-10-26 旗帜药物胶囊公司 用于制备软胶囊壁的肠溶组合物
ES2592504T3 (es) * 2003-07-17 2016-11-30 Banner Life Sciences, LLC Preparaciones de liberación controlada
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
JP2007517884A (ja) * 2004-01-09 2007-07-05 ワイス 医薬組成物用のマイクロエマルジョン
WO2006133048A2 (en) * 2005-06-03 2006-12-14 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same

Also Published As

Publication number Publication date
US8293270B2 (en) 2012-10-23
JP2013216681A (ja) 2013-10-24
EP1951208A2 (en) 2008-08-06
JP2009513657A (ja) 2009-04-02
WO2007050724A2 (en) 2007-05-03
JP5406529B2 (ja) 2014-02-05
US20070092560A1 (en) 2007-04-26
CA2627351A1 (en) 2007-05-03
WO2007050724A3 (en) 2007-09-20
CN101351196A (zh) 2009-01-21
CN101351196B (zh) 2013-07-03

Similar Documents

Publication Publication Date Title
CA2627351C (en) Lipophilic vehicle-based dual controlled release matrix system
CA2627292C (en) Hydrophilic vehicle-based dual controlled release matrix system
US10632205B2 (en) Pharmaceutical composition having reduced abuse potential
US5433951A (en) Sustained release formulation containing captopril and method
WO2004071490A1 (en) Solvent system of hardly soluble drug with improved elution rate
BR112021001345A2 (pt) formulações multiparticuladas de canabinoides
US20020160041A1 (en) Controlled release pharmaceutical composition
MX2011006307A (es) Metodos para aumentar la liberacion y absorcion de agentes activos insolubles en agua.
JP2007509155A (ja) クエチアピンを含有する薬剤
WO2009066146A2 (en) Stable solutions of sparingly soluble actives
EA035515B1 (ru) Композиции на основе дейтерированного домперидона и способы терапии расстройств
SK7342000A3 (en) Formulations comprising dissolved paroxetine
MX2007011858A (es) Formulaciones mejoradas de fenofibrato que contienen mentol o peg/poloxamero.
US20020032220A1 (en) Formulations comprising dissolved paroxetine
CN106572980A (zh) 包含他喷他多的防篡改即释胶囊制剂
MX2008005470A (en) Lipophilic vehicle-based dual controlled release matrix system as capsule fill
MX2008005474A (en) Hydrophilic vehicle-based dual controlled release matrix system as capsule fill
CA2310407A1 (en) Formulations comprising dissolved paroxetine

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20201026